To evaluate in vivo the therapeutic efficiency of the anti-HER2 Ab1' antibodies, we injected scFv40MS, scFv69MS or HER2-FcMS, NoMS (negative control) and trastuzumab (anti-HER2 antibody, positive control) in athymic nude mice (n = 5 for each group), which had been grafted four days before with HER2-positive SK-OV-3-Luc tumor cells. This evidence concerns the gene ERBB2 and neoplasm.